Skip to Content

Join the 'Myelodysplastic Syndrome' group to help and get support from people like you.

Myelodysplastic Syndrome News

Related terms: MDS

Cord-Blood Transplants Show Promise in Leukemia Treatment

Posted 8 Sep 2016 by Drugs.com

WEDNESDAY, Sept. 7, 2016 – Bone marrow or stem cell transplants can save the lives of adults and children with leukemia, but an ideal donor often isn't available. In those cases, umbilical cord blood may work as well as current alternatives – or even better in some cases, a new study suggests. "Often, cord-blood transplant is thought to be only as the last resource for patients without donors. ...

Myelodysplastic Syndrome Linked to Abnormal Stem Cells

Posted 5 Jul 2012 by Drugs.com

THURSDAY, July 5 – As researchers suspected, abnormal bone marrow stem cells trigger the development of myelodysplastic syndromes, serious blood diseases that affect the bone marrow and can progress to leukemia, according to a new study. "Good Morning America" host Robin Roberts recently disclosed that she had developed myelodysplastic syndrome, or MDS, as a rare complication of her breast ...

Drugs Previously Thought to Be Toxic May Stop Spread of Cancer

Posted 30 Mar 2012 by Drugs.com

FRIDAY, March 30 – Two drugs previously thought to be too toxic for human cancer treatment may stop the growth of cancer cells without killing healthy cells and damaging DNA when used in small doses, researchers have found. Unlike conventional chemotherapy drugs, which poison and kill any rapidly dividing cells by damaging cellular machinery and DNA, these drugs – azacitidine (AZA) and ...

Bone Marrow Cancer Patients May Benefit From Drug Combo

Posted 29 Mar 2010 by Drugs.com

MONDAY, March 29 – The drugs azacitidine and lenalidomide provide a highly effective combination treatment for bone marrow cancer, according to the results of a new study. The phase 1 study, which was funded by the U.S. National Institutes of Health, included 18 higher-risk patients, median age 68, with myelodysplastic syndromes (MDS). In people with this cancer (which is similar to leukemia), ...

FDA Approves Five-Day Dosing Regimen for Dacogen (decitabine) for Injection, Offering a New Outpatient Dosing Option for Myelodysplastic Syndromes (MDS)

Posted 15 Mar 2010 by Drugs.com

WOODCLIFF LAKE, N.J., March 11 /PRNewswire-FirstCall/ – Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved a five-day dosing regimen for Dacogen (decitabine) for Injection to treat patients with myelodysplastic syndromes (MDS), a group of bone marrow diseases that alter the production of functional blood cells. The new outpatient dosing option provides ...

Ask a Question

Further Information

Related Condition Support Groups

Myelodysplastic Diseases

Related Drug Support Groups

Vidaza, Dacogen, filgrastim, decitabine, azacitidine